E49 320
Corrigendum
Corrigendum re: ‘‘
TMPRSS2-ERG
in Blood and Docetaxel
Resistance in Metastatic Castration-resistant Prostate Cancer’’
[Eur Urol 2016;70:709–13]
O` scar Reig
a , b , 1 ,Mercedes Marı´n-Aguilera
a , c , 1 ,Gemma Carrera
d ,Natalia Jime´nez
a , c ,Laia Pare´
a , c ,Susana Garcı´a-Recio
a , c ,Lydia Gaba
b ,Maria Vero´nica Pereira
b ,Pedro Ferna´ndez
e , f ,Aleix Prat
a , b , f ,Begon˜a Mellado
a , b , *a
Translational Genomics and Targeted Therapeutics in Solid Tumours Group, Institut d’Investigacions Biome`diques August Pi i Sunyer (IDIBAPS), Barcelona,
Spain;
b
Medical Oncology Department, Hospital Clı´nic, Barcelona, Spain;
c
Fundacio´ Clı´nic per a la Recerca Biome`dica, Barcelona, Spain;
d
Medical Oncology
Department, Hospital Plato´, Barcelona, Spain;
e
Department of Pathology, Hospital Clo´nic, Barcelona, Spain;
f
University of Barcelona, Barcelona, Spain
The following information was inadvertently omitted:
Funding/Support and role of the sponsor:
This work was co-financed by European Development Regional Fund (ERDF).
Conflicts of interest:
The authors have nothing to disclose.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) e 4 9ava ilable at
www.sciencedirect.comjournal homepage:
www.eu ropeanurology.comDOI of original article:
http://dx.doi.org/10.1016/j.eururo.2016.02.034.
* Corresponding author. Medical Oncology Department, Hospital Clı´nic of Barcelona, Villarroel 170, Barcelona 08036, Spain. Tel.
+34 93 227 54 00
;
Fax: +34 93 454 65 20.
E-mail address:
bmellado@clinic.ub.es(B. Mellado).
1
These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.eururo.2017.02.0270302-2838/